Chemical Structure (Zavegepant 01)
Chemical structure of zavegepant hydrochloride, the active ingredient in the prescription nasal spray product ZAVZPRET.*
Zavzpret Spray
Product Images NDC 63539-135
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 24 technical images submitted to the FDA as part of the official labeling for Zavzpret (NDC 63539-135). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by U.s. Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Zavegepant 02)
Line graph comparing the percent of subjects achieving pain freedom over time between ZAVZPRET nasal spray 10 mg and placebo. The x-axis shows time in hours from dose (0 to 2 hours) and the y-axis shows percent achieving pain freedom (0% to 100%). ZAVZPRET shows a higher percentage over time than placebo.*
Figure 2 (Zavegepant 03)
A line graph comparing the percentage of subjects achieving most bothersome symptom freedom over 2 hours after dosing with ZAVZPRET nasal spray 10 mg versus placebo. The x-axis represents time in hours post dose (0 to 2 hours), and the y-axis shows the percent symptom freedom from 0% to 100%. Two lines are plotted: one for ZAVZPRET nasal spray showing a gradual increase up to about 40%, and a lower line for placebo reaching about 30%.*
Figure 3 (Zavegepant 04)
A line graph comparing the percent of subjects achieving pain freedom over time between ZAVZPRET nasal spray 10 mg and placebo. The X-axis shows time in hours from dose (0 to 2 hours), and the Y-axis indicates percent achieving pain freedom (0% to 100%). ZAVZPRET shows a gradual increase in pain freedom attainment, higher than placebo throughout the 2-hour period.*
Figure 4 (Zavegepant 05)
A line graph comparing percent achieving most bothersome symptom freedom over 2 hours between ZAVZPRET nasal spray 10 mg and placebo. The x-axis shows time in hours from dose (0 to 2 hours) and the y-axis shows percent achieving symptom freedom (0% to 100%). ZAVZPRET shows higher percent symptom freedom over time than placebo.*
Logo (Zavegepant 06)
Logo (Zavegepant 07)
Figure A (Zavegepant 08)
Illustration showing a nasal spray device for ZAVZPRET 10 mg/0.1 mL with labeled parts: a sprayer nozzle inserted into the nose and a plunger that is pressed with the thumb to dispense the medication.*
Figure B (Zavegepant 09)
Illustration labeled Figure B showing a person pressing a nasal area with both hands over a cloth or tissue. The image appears instructional, likely related to the use of a nasal spray product.*
Figure C (Zavegepant 10)
An instructional illustration showing a hand removing one nasal spray device from a box containing multiple devices arranged in individual slots. The image emphasizes removing only one device at a time from the packaging for the ZAVZPRET nasal spray.*
Figure D (Zavegepant 11)
An instructional illustration showing a hand holding a ZAVZPRET nasal spray device near a human nose, demonstrating the correct use of the spray by directing it into the nostril. The image includes a partial view of the spray device and an arrow indicating the spray's direction into the nose.*
Figure E (Zavegepant 12)
An instructional illustration labeled Figure E showing hands peeling back the cover of a blister pack containing a single unit of product ZAVZPRET nasal spray. The image demonstrates the steps for preparing the nasal spray for use.*
Figure F (Zavegepant 13)
An instructional diagram showing nasal spray administration. The image depicts a spray device positioned near a human nose, demonstrating the direction to use the nasal spray. The spray is intended for nasal route delivery.*
Figure G (Zavegepant 14)
An instructional illustration showing a hand holding a nasal spray device with the thumb positioned on the bottom for activation. The spray nozzle is directed upward, demonstrating the proper grip and use of the nasal spray.*
Figure H (Zavegepant 15)
An instructional diagram illustrating the proper technique for administering a nasal spray. The image shows a person holding a finger near a nostril with an arrow pointing into the nostril, indicating direction for nasal spray insertion or usage.*
Figure I (Zavegepant 16)
An instructional illustration showing a person using a nasal spray. The image demonstrates the correct technique for administering the spray into the nostril with one hand holding the spray device and the other hand positioned to support or open the opposite nostril.*
Figure J (Zavegepant 17)
Illustration showing the use of a nasal spray device. It depicts a hand pressing down firmly on the plunger of the spray while another hand holds the spray near a nostril, indicating breathing in through the nose as the spray is administered.*
Figure K (Zavegepant 18)
An instructional diagram showing a person breathing with the head level and upright. Arrows indicate to breathe in through the nose and breathe out through the mouth for 10-20 seconds. A clock graphic highlights the 10-20 second duration. Text below instructs to gently breathe in through the nose and out through the mouth for 10-20 seconds.*
Figure L (Zavegepant 19)
Illustration showing a hand holding a nasal spray device above a trash bin labeled "TRASH," indicating proper disposal of the spray device.*
Logo (Zavegepant 20)
Principal Display Panel – Nasal Spray Device Label Front Sample (Zavzpret 07)
Label for Zavzpret nasal spray 10 mg (zavegepant) by U.S. Pharmaceuticals. The label indicates it is a professional sample not for sale, for intranasal use only, Rx only, with NDC 63539-135-01. Instructions caution not to test the spray and to prime or press the plunger before use.*
Principal Display Panel – Nasal Spray Device Label Back Sample (Zavzpret 08)
ZAVZPRET nasal spray label showing the U.S. Pharmaceuticals and Pfizer Inc. names. The label includes placeholder text for lot number and expiration date in a black section with white text, and a curved pink outline design.*
Principal Display Panel – Nasal Spray Blister Foil Label Sample (Zavzpret 09)
ZAVZPRET nasal spray 10 mg label showing the proprietary name and active ingredient zavegepant. The label states it is a professional sample, not for sale, and contains one spray per unit dose. It includes storage instructions and warnings, and indicates distribution by U.S. Pharmaceuticals, Pfizer Inc., New York, NY.*
Principal Display Panel – Nasal Spray Carton Sample (Zavzpret 10)
ZAVZPRET nasal spray 10 mg packaging label displays the proprietary name ZAVZPRET with the generic name zavegepant. It indicates a 10 mg nasal spray dosage form for intranasal use. The label includes storage instructions, contents of the box, and warnings. The labeler is U.S. Pharmaceuticals and Pfizer Inc. It is marked as Rx only and professional sample not for sale.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
